New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:07 EDTCELG, CNCE, JAZZConcert Pharmaceuticals reports FY13 EPS ($4.99) vs. (16.15) last year
Concert Pharmaceuticals reports FY13 revenue $25.4M vs. $12.8M last year. The company said, "The increase in revenue was primarily due to license and research and development revenue of $17M and $3.7M recognized for the year ended December 31, 2013 in connection with collaborations entered into with Celgene (CELG) and Jazz Pharmaceuticals (JAZZ) respectively, during 2013."
News For CNCE;CELG;JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 25, 2015
13:44 EDTCELGCelgene price target raised to $155 from $130 at Argus
Argus increased its price target on Celgene as the firm thinks the company is "well on its way" to meeting its growth targets. The firm thinks the company reported strong Q4 results and keeps a Buy rating on the shares.
10:47 EDTJAZZJazz Pharmaceuticals participates in a conference call with BMO Capital
BMO Capital's Specialty Pharma Analyst Maris hosts a conference call with Jazz's CEO, Bruce Cozadd, on February 25 at 2:30 pm.
07:31 EDTJAZZJazz Pharmaceuticals pullback a buying opportunity, says JPMorgan
JPMorgan says Jazz Pharmaceuticals' weaker than expected 2015 earnings outlook was not driven by any softness in the company's core driver, Xyrem, but rather non-operating/one-off issues. The firm recommends using the share sell-off as a buying opportunity and keeps an Overweight rating on Jazz with a $190 price target.
February 24, 2015
16:18 EDTJAZZJazz Pharmaceuticals announces retirement of CMO
Subscribe for More Information
16:17 EDTJAZZJazz Pharmaceuticals sees 2015 EPS $9.45-$9.75, consensus $10.11
Subscribe for More Information
16:16 EDTJAZZJazz Pharmaceuticals reports Q4 EPS $2.44, consensus $2.30
Subscribe for More Information
15:21 EDTJAZZNotable companies reporting after market close
Subscribe for More Information
08:04 EDTCELGCelgene reports Abraxane now reimbursed in Italy as first-line treatment
Celgene International SÓrl, a wholly owned subsidiary of Celgene Corporation, announced that Italian authorities have issued a positive decision for NHS reimbursement of ABRAXANE -- paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel -- in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, or pancreatic cancer. The reimbursement decision has been published in the Italian Official Gazette no. 30, dated February 6, 2015.
07:31 EDTCELGRBC Capital to hold a conference
Subscribe for More Information
February 20, 2015
16:03 EDTCELGOptions Update; February 20, 2015
Subscribe for More Information
13:38 EDTJAZZLeerink specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information
10:01 EDTJAZZOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Advanced Drainage (WMS) initiated with an Outperform at Boenning & Scattergood... Arctic Cat (ACAT) initiated with a Hold at BB&T... Ardmore Shipping (ASC) initiated with an Accumulate at Global Hunter... Baltic Trading (BALT) initiated with a Speculative Buy at Global Hunter... Cash America (CSH) initiated with a Buy at Jefferies... Costamare (CMRE) initiated with an Accumulate at Global Hunter... DHT Holdings (DHT) initiated with a Buy at Global Hunter... Danaos (DAC) initiated with a Neutral at Global Hunter... Diana Containerships (DCIX) initiated with a Neutral at Global Hunter... Diana Shipping (DSX) initiated with a Neutral at Global Hunter... Euronav NV (EURN) initiated with a Buy at Global Hunter... Forest City (FCE.A) initiated with a Neutral at Citigroup... Fox Factory (FOXF) initiated with a Hold at BB&T... Frontline (FRO) initiated with an Accumulate at Global Hunter... Global Ship Lease (GSL) initiated with a Neutral at Global Hunter... GrubHub (GRUB) initiated with an Overweight at Barclays... Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at BMO Capital... Kinder Morgan (KMI) reinstated with an Overweight at Barclays... Liberty Broadband (LBRDA) initiated with an Outperform at FBN Securities... Liberty Interactive (QVCA) initiated with a Sector Perform at FBN Securities... Liberty Media (LMCA) initiated with an Outperform at FBN Securities... MEI Pharma (MEIP) initiated with a Buy at BofA/Merrill... Navios Acquisition (NNA) initiated with a Buy at Global Hunter... Polaris Industries (PII) initiated with a Buy at BB&T... Raven (RAVN) initiated with an Equal Weight at Stephens... Scorpio Bulkers (SALT) initiated with a Speculative Buy at Global Hunter... Scorpio Tankers (STNG) initiated with an Accumulate at Global Hunter... Seaspan (SSW) initiated with a Neutral at Global Hunter... Star Bulk Carriers (SBLK) initiated with a Speculative Buy at Global Hunter... Tsakos Energy (TNP) initiated with a Buy at Global Hunter... U.S. Concrete (USCR) initiated with an Overweight at Stephens.
09:38 EDTCELGActive equity options trading on open
Subscribe for More Information
05:40 EDTJAZZJazz Pharmaceuticals initiated with an Outperform at BMO Capital
Subscribe for More Information
05:27 EDTCELGCelgene Revlimid approved by EC
Subscribe for More Information
February 18, 2015
16:00 EDTCELGOptions Update; February 18, 2015
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTCELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use